CTNNA2

Across TCGA pan-cancer cohorts, CTNNA2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CTNNA2 data layer compared with 24 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CTNNA2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CTNNA2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where CTNNA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.314	0.904	.002	11	view →
HNSC	DFS	Tertile	All	0.773	0.308	.036	8	view →
LUAD	OS	Tertile	All	0.385	1.000	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CTNNA2–PDAC (DFS)

Open the PDAC breakdown →